These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 12072912)

  • 1. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
    Keeling KM; Bedwell DM
    J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
    Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
    J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Readthrough of dystrophin stop codon mutations induced by aminoglycosides.
    Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM
    Ann Neurol; 2004 Mar; 55(3):422-6. PubMed ID: 14991821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
    Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
    Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
    Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
    Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro.
    Popescu AC; Sidorova E; Zhang G; Eubanks JH
    J Neurosci Res; 2010 Aug; 88(11):2316-24. PubMed ID: 20623622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
    Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
    RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
    Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
    Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.
    Ngiwsara L; Sawangareetrakul P; Wattanasirichaigoon D; Tim-Aroon T; Dejkhamron P; Champattanachai V; Ketudat-Cairns JR; Svasti J
    Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):147-154. PubMed ID: 36332477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.
    Baradaran-Heravi A; Niesser J; Balgi AD; Choi K; Zimmerman C; South AP; Anderson HJ; Strynadka NC; Bally MB; Roberge M
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3479-3484. PubMed ID: 28289221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
    Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
    Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.
    Du M; Jones JR; Lanier J; Keeling KM; Lindsey JR; Tousson A; Bebök Z; Whitsett JA; Dey CR; Colledge WH; Evans MJ; Sorscher EJ; Bedwell DM
    J Mol Med (Berl); 2002 Sep; 80(9):595-604. PubMed ID: 12226741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.
    Manuvakhova M; Keeling K; Bedwell DM
    RNA; 2000 Jul; 6(7):1044-55. PubMed ID: 10917599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential.
    Friesen WJ; Johnson B; Sierra J; Zhuo J; Vazirani P; Xue X; Tomizawa Y; Baiazitov R; Morrill C; Ren H; Babu S; Moon YC; Branstrom A; Mollin A; Hedrick J; Sheedy J; Elfring G; Weetall M; Colacino JM; Welch EM; Peltz SW
    PLoS One; 2018; 13(10):e0206158. PubMed ID: 30359426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional, histological, biochemical renal modifications. Comparative study of dibekacin, gentamicin, tobramycin, netilmicin and amikacin].
    Viotte G; Olier B; Morin JP; Godin M
    Nouv Presse Med; 1982 Nov; 11(46):3419-25. PubMed ID: 7155850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].
    Jotzoff M
    Med Klin; 1978 Jun; 73(24):914-7. PubMed ID: 661734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycosides and other factors promoting stop codon readthrough in human cells.
    Diop D; Chauvin C; Jean-Jean O
    C R Biol; 2007 Jan; 330(1):71-9. PubMed ID: 17241950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.